𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets

✍ Scribed by Michael J. Jackson; Lance A. Smith; Ghassan Al-Barghouthy; Sarah Rose; Peter Jenner

Book ID
116459057
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
242 KB
Volume
204
Category
Article
ISSN
0014-4886

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel antiepileptic drug levetiracetam d
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset
✍ Michael P. Hill; Erwan Bezard; Steven G. McGuire; Alan R. Crossman; Jonathan M. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract Long‐term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus pallidus, involving a pathological synchronization/desynchronization process, may contribute significantly to the genesis of dy

De novo administration of ropinirole and
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
✍ Ronald K. B. Pearce; Tara Banerji; Professor Peter Jenner; C. David Marsden 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 760 KB

## Abstract In contrast to levodopa (L‐dopa), de novo administration of the D2‐like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated subhuman primates is not associated with the onset of significant dyskinesia

Repeated administration of piribedil ind
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation
✍ Lance A. Smith; Banu C. Tel; Michael J. Jackson; Matthew J. Hansard; Rogelio Bra 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 615 KB

## Abstract Piribedil ([1‐(3,4‐methylenedioxybenzyl)‐4‐(2‐pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D~2~/D~3~ dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L‐dopa). However, its ability to prime basal g

Antiparkinsonian activity and dyskinesia
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)
✍ Eleni C. Maratos; Michael J. Jackson; Ronald K. B. Pearce; Peter Jenner 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

## Abstract De novo administration of long‐acting dopamine agonists, such as ropinirole, to patients with Parkinson's disease or to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated subhuman primates produces a lower incidence of dyskinesia than occurs with L‐DOPA. This study compares the